Compare KROS & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KROS | LFCR |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | 382 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 196.9M |
| IPO Year | 2020 | 1996 |
| Metric | KROS | LFCR |
|---|---|---|
| Price | $11.26 | $5.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $21.86 | $6.00 |
| AVG Volume (30 Days) | ★ 277.5K | 230.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $243,864,000.00 | ★ $557,559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,751.79 | $5.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $9.69 | $3.63 |
| 52 Week High | $22.55 | $8.98 |
| Indicator | KROS | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 44.68 |
| Support Level | $10.64 | $4.75 |
| Resistance Level | $11.55 | $5.35 |
| Average True Range (ATR) | 0.50 | 0.32 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 85.91 | 25.55 |
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.